Abstracts

Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide PI Susceptibility

Background: Protease inhibitor (PI)- based regimens are the mainstay of antiretroviral therapy for HIV-2. However, HIV-2 exhibits some degree of intrinsic resistance to the majority of FDA-approved PI, only retaining clinically-useful susceptibility to lopinavir, darunavir, and saquinavir. The mechanisms for this resistance remain largely unknown; although HIV-1 and HIV-2 proteases share only 40-50% sequence identity,…

Mutations at the Bottom of the Phe43 Cavity Are Responsible for Cross-Resistance to NBD Analogues

Background: CD4 mimic small compounds (CD4MCs), NBD-556 and its analogues, inhibit the gp120-CD4 interaction and can also induce conformational changes in the gp120 architecture thereby exposing masked epitopes of neutralizing antibodies on the Env protein. Recently, some groups have reported novel potent NBD analogues. We designed and synthesized five new NBD analogues (YIR compounds). In…

SIVmac239 Integrase as a Model of HIV Drug Resistance Against Integrase Inhibitors

Background: We previously showed that SIVmac239 is susceptible to raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG) with IC50s in the nanomolar range, and integrase (IN) mutant viruses displayed similar resistance profiles to HIV. A long-acting form of a new INSTI termed S/GSK-1265744, a DTG analogue, was shown to protect macaques against repeated vaginal and rectal…

Within-Run Cross-Contamination in Deep Sequencing Applications on the Illumina MiSeq

Background: The Illumina MiSeq DNA sequencing system generates several gigabases of short reads per run with a relatively low error rate. We previously described longitudinal contamination on this platform which has since been addressed by a post-run bleach wash. Here we characterize rates and sources of systematic low level, within-run cross-sample contamination, an under-reported issue…

HIV-1 Subtype Influences the Pathways of Genotypic Resistance to Integrase Inhibitors

Background: The mutational profiles selected in vivo by integrase inhibitors (INIs) have been primarily defined within clinical trials that involved predominantly subjects with HIV-1 subtype B infection. CORONET is multicentre surveillance programme that aims to characterise INI-resistance in diverse INI-naïve and INI-experienced European cohorts. This analysis addressed the influence of HIV-1 subtype on pathways of…

Differences in Resistance Mutations in Non-B Subtypes at First-Line Failure in Africa

Background: Resistance mutations may vary by viral subtype, although data to date are limited, especially for non-B subtypes. Understanding the common mutational patterns is important for determining the optimal standardised regimens for the public health approach to ART in settings without resistance testing or individualised therapy. Methods: Genotypes were obtained from stored baseline samples from…

Viral Failure and High K65R in Kenyan Patients on Tenofovir-Based First-Line Therapy

Background: Tenofovir (TDF)-based 1st-line antiretroviral therapy (ART) is globally recommended by the World Health Organization (WHO). Effects of switching from prior non-TDF to TDF-based regimens on ART success are unknown. High rates of the TDF-associated K65R mutation in HIV-1 subtype C, but not B, are reported, associated with a poly-A template in reverse transcriptase (RT)…

Large NNRTI-Resistant Transmission Cluster in Injection Drug Users From Saskatchewan

Background: Saskatchewan, a Canadian Prairie province, is currently experiencing a unique HIV epidemic characterized by high rates of transmission through injection drug use. Aboriginal peoples are disproportionately affected. Methods: We reviewed the epidemiologic and clinical characteristics of all HIV-positive individuals who attend the Regina Qu’Appelle Health Region Infectious Diseases Clinic, which serves the southern half…